PharmaCyte Biotech Inc Cash Flow-to-Debt Ratio
PharmaCyte Biotech Inc cash flow-to-debt ratio. PharmaCyte Biotech Inc (PMCB) has a Cash Flow-to-Debt Ratio of -0.12x as of April 2026, meaning its operating cash flow of $-1.39 Million could theoretically repay 0% of its total liabilities ($11.77 Million) in one year. Check PMCB cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of PharmaCyte Biotech Inc (2002–2026)
Cash flow-to-debt ratio of PharmaCyte Biotech Inc from 2002 to 2026. Historical debt coverage capacity for PharmaCyte Biotech Inc across 25 annual periods. Check PMCB total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
PharmaCyte Biotech Inc Cash Flow-to-Debt Ratio by Year (2002–2026)
PharmaCyte Biotech Inc cash flow-to-debt ratio by year from 2002 to 2026. Year-by-year debt coverage analysis for PharmaCyte Biotech Inc. For the full cash flow conversion analysis, see PharmaCyte Biotech Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -0.44x | $-5.15 Million | $11.77 Million | ▲ +51.8% |
| 2025 | -0.91x | $-2.98 Million | $3.28 Million | ▼ -761.2% |
| 2024 | -0.11x | $-2.15 Million | $20.39 Million | ▲ +98.4% |
| 2023 | -6.47x | $-3.79 Million | $586.58K | ▼ -10.6% |
| 2022 | -5.85x | $-4.12 Million | $704.37K | ▼ -27.2% |
| 2021 | -4.60x | $-3.33 Million | $724.78K | ▼ -111.8% |
| 2020 | -2.17x | $-2.34 Million | $1.08 Million | ▲ +44.0% |
| 2019 | -3.87x | $-2.88 Million | $742.85K | ▲ +50.9% |
| 2018 | -7.89x | $-5.08 Million | $644.17K | ▼ -37.0% |
| 2017 | -5.76x | $-3.34 Million | $580.25K | ▲ +15.6% |
| 2016 | -6.82x | $-4.35 Million | $637.64K | ▼ -200.8% |
| 2015 | -2.27x | $-4.56 Million | $2.01 Million | ▲ +45.8% |
| 2014 | -4.18x | $-1.56 Million | $373.67K | ▼ -3968.3% |
| 2013 | -0.10x | $-390.43K | $3.80 Million | ▼ -50.1% |
| 2012 | -0.07x | $-259.29K | $3.79 Million | ▼ -20.7% |
| 2011 | -0.06x | $-225.23K | $3.97 Million | ▲ +81.6% |
| 2010 | -0.31x | $-974.06K | $3.15 Million | ▲ +24.0% |
| 2009 | -0.41x | $-1.19 Million | $2.92 Million | ▲ +93.8% |
| 2008 | -6.60x | $-1.19 Million | $180.56K | ▼ -122.9% |
| 2007 | -2.96x | $-351.60K | $118.81K | ▼ -99.8% |
| 2006 | -1.48x | $-1.07 Million | $723.89K | ▲ +13.6% |
| 2005 | -1.71x | $-2.80 Million | $1.63 Million | ▼ -155.4% |
| 2004 | -0.67x | $-221.03K | $329.13K | ▲ +95.5% |
| 2003 | -14.84x | $-37.46K | $2.52K | ▼ -429.9% |
| 2002 | -2.80x | $-21.99K | $7.86K | — |